JAKARTA PT Pyridam Farma Tbk (PYFA GROUP, stock code: PYFA) through its subsidiary, PT Ethica Industri Farmasi, has expanded their injection product manufacturing facilities to increase production capacity by up to 3 times.
President Director of PT Ethica Industri Pharmacy Pierana Evy said the expansion of the facility was carried out to meet hospital demand for injection products that have increased rapidly in recent years.
"The increase in demand for injection products is the main motivation for us to expand," he said as quoted by ANTARA, Thursday, September 12.
The expansion of these facilities is designed and equipped with advanced and modern production technology that meets the standards of commercial Good Manufacturing Practices (cGMP) Indonesia and international, Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S).
Production technology at the facility also meets the requirements of European Union Good Manufacturing Practices (EU GMP) and Australia's Therapeutic Goods Administration (TGA).
According to Merciana, the effort shows his party's readiness to penetrate a broader global market.
"With increased production capacity, we are ready to meet the needs of high-quality drugs, both in the domestic and international markets," he said.
With this expansion, he stated that his party was further strengthening the company's position as one of the leading pharmaceutical companies in Indonesia.
SEE ALSO:
It is also ready to become a major player in the global pharmaceutical industry, focusing on the development and production of innovative drugs.
"As part of the PYFA GROUP extended family, we continue to be committed to innovating and making a bigger contribution to the Indonesian pharmaceutical industry," said Merciana.
Groundbreaking for the expansion of the injection product manufacturing facility takes place in the Cikarang Industrial Estate, Bekasi, West Java, Monday, September 9.
The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)